Université de Montréal researchers have found that fear of hypoglycemia (low blood sugar) act as major reason for physical inactivity among diabetics. The study confirms earlier studies that found 60 percent of adult diabetics aren’t physically active.
Report shows that in sample population (75.1 million) for which the incidence of type 1 diabetes is estimated covers 4.5% of the world’s population. In this type 1 diabetic population approximately 30,000 are Americans and near about 50% are children.
Liraglutide the Novo Nordisk’s experimental type 2 diabetes drug is proved to control the blood sugar better. In a 26 week long head to head trial this Danish company finds that the patients given the liraglutide once a day have received a reduction of 1.1 percent in HCA1c levels, a key ingredient in blood sugar. Thus the drug works a step ahead of the other drug Byetta that has recorded less than 0.8% reduction in the blood sugar. Nearly 55% of the liraglutide patients reached the ADA target compared with close to 45 percent on Byetta, known chemically as exenatide. The company Novo Nordisk is looking forward to European and American approval next month.
The recent study by the Sydney based George Institute for International Health, finds out that by lowering the blood glucose level, patients can reduce the risk of type 2 diabetes by 10%. It also finds that well controlled blood glucose can cut down various other risks of renal disease and cardiovascular risks by 21% and 30% respectively. The study has covered a long period of five years and involved around 11,000 people in various countries.